On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & ...

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu), a human FcRn-blocking ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

The U.S. FDA approval of Johnson & Johnson’s Imaavy (nipocalimab-aahu) for myasthenia gravis brings the monoclonal antibody into a treatment space that has plenty of competition. The human Fc receptor ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

As a result, the muscles become weak when a person performs repeated physical movements. The disease is neither contagious nor inherited but it is often misunderstood as a psychological issue or ...

A key secondary endpoint was change from baseline in Quantitative Myasthenia Gravis scale (QMG) score at week 26 in the combined patient population. Results show that patients administered Uplizna ...